Patents Assigned to Universitaet Zu Koeln
-
Publication number: 20240327817Abstract: The present invention provides an isolated protein exhibiting an antiaggregating activity and/or disaggregating activity toward a target protein comprising an extended polyQ stretch. The protein comprises a Zn2+-binding region, wherein the conserved motif is HxxEHx75-80E and x is any amino acid. The nucleic acid construct encoding said protein as well as the corresponding mRNA sequence are also provided. The protein, the nucleic acid construct or mRNA sequence are for use in a method for prevention or treatment of a neurodegenerative disease that is caused by aggregates comprising at least one target protein and/or by the mRNA encoding for said target protein, wherein the target protein causes e.g. Huntington's disease or Machado-Joseph disease.Type: ApplicationFiled: February 23, 2024Publication date: October 3, 2024Applicant: Universität zu KölnInventors: Ernesto LLAMAS PAMANES, David VILCHEZ GUERRERO, Alga ZUCCARO
-
Patent number: 11931242Abstract: A device for the preparation of a Descemet's membrane-endothelium graft includes a bowl with an inner bottom and a sidewall surrounding the bottom, particularly the bowl being configured to receive a fluid and a Descemet's membrane-endothelium graft or a donor cornea graft comprising a Descemet's membrane-endothelium graft floating in the fluid, a preparation area positioned in a first part of the inner bottom of the bowl, particularly for receiving and preparing the graft prior to transport, a transfer area positioned in a second part of the inner bottom between the preparation area and an outlet opening in the sidewall, particularly the opening being entirely positioned below the upper rim of the sidewall.Type: GrantFiled: August 13, 2020Date of Patent: March 19, 2024Assignee: UNIVERSITAET ZU KOELNInventors: Claus Cursiefen, Bjoern Bachmann, Sebastian Siebelmann
-
Patent number: 11774441Abstract: The present invention relates to a method for determining the fertility of spermatozoa, said method comprising determining the total content of Vimentin variant 3 (Vim3) per spermatozoon and/or the spatial localization of the Vim3 in the spermatozoa, wherein a decreased amount of total content and/or decreased amount of (or even missing) accumulation of Vim3 in the mid piece of the spermatozoa indicates decreased fertility. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.Type: GrantFiled: April 6, 2018Date of Patent: October 3, 2023Assignee: Universität zu KölnInventors: Melanie von Brandenstein, Ali Tok
-
Publication number: 20230119290Abstract: The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.Type: ApplicationFiled: March 18, 2021Publication date: April 20, 2023Applicant: Universität Zu KölnInventors: Henning HAGMANN, Thomas BENZING, Bernhard SCHERMER, Manuel KOCH, Mahsa MATIN
-
Patent number: 11609231Abstract: Methods, kits, and active ingredients for diagnosing or treating arthritis or a degenerative disease of the skeletal system, or for selection of subjects for therapy. The methods for diagnosing arthritis involve the detection of an autoantibody, which is associated with arthritis, or excluding the presence of an autoantibody against collagen II. The methods for diagnosing a degenerative disease of the skeletal system, involve the detection of an autoantibody against thrombospondin-4 or COMP. The kits contain a detection agent for an autoantibody and can be used for diagnosing arthritis or a degenerative disease of the skeletal system. The active ingredient can be used for treating or preventing autoimmune-associated arthritis.Type: GrantFiled: December 12, 2018Date of Patent: March 21, 2023Assignee: UNIVERSITÄT ZU KÖLNInventors: Andreas R. Klatt, Johannes Ruthard, Benedikt Ostendorf, Matthias Schneider, Georg Pongratz, Gabriele Hermes
-
Patent number: 11542234Abstract: 6-[18F]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]PSMA-1007 and [Al18F]HBED-CC-PSMA. Unexpectedly, the 6-[18F]fluoro-2-alkoxy and 6-[18F]fluoro-4-alkoxy substituted analogs showed significant differences in accumulation in PSMA expressing prostate tumor cells. Whereas the 2-alkoxy derivative showed cellular uptake values higher than [18F]DCFPyL, the cellular uptake of the corresponding 4-alkoxy substituted derivative was significantly lower. Furthermore, in vivo PET studies with 2-alkoxy-substituted probes demonstrated excellent visualization of PSMA positive ganglia with extremely high target to background ratio. In contrast, the 4-alkoxy substituted derivatives showed less favorable biodistribution with significantly lower uptake in PSMA positive tissues.Type: GrantFiled: March 15, 2019Date of Patent: January 3, 2023Assignee: Universität zu KölnInventors: Bernd Neumaier, Boris Zlatopolskiy, Philipp Krapf, Raphael Richarz, Alexander Drzezga
-
Patent number: 11299453Abstract: The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating cells or differentiated cells derived from the pluripotent stem cells, the method comprising the step of contacting the cell population with a compound according to the general formula (1).Type: GrantFiled: November 6, 2018Date of Patent: April 12, 2022Assignee: Universität zu KölnInventors: Tomo Saric, Albrecht Berkessel, Karsten Burkert, Jürgen Hescheler
-
Publication number: 20210340489Abstract: A method of culturing Haematococcus species for manufacturing of astaxanthin comprising the steps of: providing a substrate, arranging the Haematococcus species on the surface of the substrate, exposing the Haematococcus species arranged on the substrate to high light intensities from the beginning of a culturing process and avoiding a two-step culturing process of the Haematococcus species with a first step which is an initial culturing taking place by exposure of the Haematococcus species to low light energy followed by a second step of subsequent culturing of the Haematococcus species by exposure of the Haematococcus species to higher light energy than applied in the first step to induce astaxanthin formation, and optionally—harvesting the cultured Haematococcus species and/or—isolating astaxanthin.Type: ApplicationFiled: July 8, 2021Publication date: November 4, 2021Applicant: UNIVERSITÄT ZU KÖLNInventors: Bjorn Podola, Michael Melkonian, Alice Costa Kiperstok, Petra Sebestyen
-
Publication number: 20210148914Abstract: The present invention relates to a method for detecting malignant kidney cancer in an individual, said method conducted in vitro comprising the steps of providing a body fluid sample, in particular a urine sample, obtained from the individual, and determining one or more biomarker levels selected from the group consisting of the Mxi-2 level, the Vim3 level, the MAPKp38 level and the Atg7 level in the sample. Further, the present invention refers to a kit and a dipstick for use in such method.Type: ApplicationFiled: July 10, 2018Publication date: May 20, 2021Applicant: Universität zu KölnInventors: Melanie von Brandenstein, Jochen Fries
-
Publication number: 20210109097Abstract: The invention relates to a method for diagnosing arthritis, comprising the detection of an autoantibody, which is associated with arthritis, to a method for diagnosing a degenerative disease of the skeletal system, comprising the detection of an autoantibody against thrombospondin-4 or COMP, to a method for diagnosing arthritis, comprising excluding the presence of an autoantibody against collagen II, to a kit for diagnosing arthritis or a degenerative disease of the skeletal system, comprising a detection agent for an autoantibody, to the use of the kit for diagnosing arthritis or a degenerative disease of the skeletal system, to an active ingredient for use for treatment or preventing autoimmune-associated arthritis and to the diagnostic method for selection of subjects for therapy.Type: ApplicationFiled: December 12, 2018Publication date: April 15, 2021Applicant: UNIVERSITÄT ZU KÖLNInventors: Andreas R. Klatt, Johannes Ruthard, Benedikt Ostendorf, Matthias Schneider, Georg Pongratz, Gabriele Hermes
-
Publication number: 20210032206Abstract: 6-[18F]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]PSMA-1007 and [Al18F]HBED-CC-PSMA. Unexpectedly, the 6-[18F]fluoro-2-alkoxy and 6-[18F]fluoro-4-alkoxy substituted analogs showed significant differences in accumulation in PSMA expressing prostate tumor cells. Whereas the 2-alkoxy derivative showed cellular uptake values higher than [18F]DCFPyL, the cellular uptake of the corresponding 4-alkoxy substituted derivative was significantly lower. Furthermore, in vivo PET studies with 2-alkoxy-substituted probes demonstrated excellent visualization of PSMA positive ganglia with extremely high target to background ratio. In contrast, the 4-alkoxy substituted derivatives showed less favorable biodistribution with significantly lower uptake in PSMA positive tissues.Type: ApplicationFiled: March 15, 2019Publication date: February 4, 2021Applicant: Universität zu KölnInventors: Bernd NEUMAIER, Boris ZLATOPOLSKIY, Philipp KRAPF, Raphael RICHARZ, Alexander DRZEZGA
-
Patent number: 10874504Abstract: A device for the transplantation of a Descemet's membrane includes a longitudinal tube having an inner cavity, an inlet opening through which it is possible to introduce the Descemet's membrane into the device, and an outlet opening through which it is possible to eject the Descemet's membrane from the device, especially into the anterior eye chamber of a patient, wherein the device also includes, at least in the region of the outlet opening, a separation element which protrudes from the inner wall region of the tube into the cavity, especially a first separation element, the separation element dividing the cavity at least regionally, in particular dividing it in a region close to the separation element.Type: GrantFiled: June 27, 2017Date of Patent: December 29, 2020Assignee: UNIVERSITAET ZU KOELNInventors: Bjoern Bachmann, Sebastian Siebelmann, Claus Cursiefen
-
Patent number: 10875856Abstract: The invention relates to CPAP-tubulin inhibitors having the general formula (1) or a physiologically acceptable salt thereof; and their use as cancer therapeutics.Type: GrantFiled: December 8, 2016Date of Patent: December 29, 2020Assignees: UNIVERSITAET ZU KOELN, HELMHOLTZ ZENTRUM MUENCHENInventors: Kamyar Hadian, Karl Kenji Schorpp, Michael Sattler, Komal Soni, Jay Gopalakrishnan
-
Publication number: 20200383995Abstract: The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine/threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of ?B (I?B) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.Type: ApplicationFiled: December 7, 2018Publication date: December 10, 2020Applicant: Universität zu KölnInventors: Manolis PASPARAKIS, Nikos OIKONOMOU, Apostolos POLYKRATIS
-
Patent number: 10822378Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: GrantFiled: April 10, 2017Date of Patent: November 3, 2020Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin Lux, Hildegard Buening, John Nieland, Jorge Boucas, Mirko Ritter, Markus Hoerer, Luca Perabo, Michael Hallek
-
Publication number: 20200339502Abstract: The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating cells or differentiated cells derived from the pluripotent stem cells, the method comprising the step of contacting the cell population with a compound according to the general formula (1).Type: ApplicationFiled: June 11, 2018Publication date: October 29, 2020Applicant: Universität zu KölnInventors: Tomo SARIC, Albrecht BERKESSEL, Karsten BURKERT, Jürgen HESCHELER
-
Publication number: 20200232044Abstract: The present invention relates to methods for detecting a malignant tumor in an individual by means of determining the Vimentin variant 3 (Vim3) level in the individual's blood serum S and/or the accumulation of Vim3 polypeptide in cell nuclei. Furthermore, the present invention refers to an antineoplastic agent for use in a method for treating an individual bearing a malignant tumor, wherein said antineoplastic agent is a Vim3 inhibitor and/or wherein the malignant tumor is endothelin B receptor negative.Type: ApplicationFiled: October 2, 2018Publication date: July 23, 2020Applicant: Universität zu KölnInventors: Melanie von Brandenstein, Jochen Fries, Tobias Kohl, Monika Stefanie Schlosser, Andreas Stog
-
Publication number: 20200110076Abstract: The present invention relates to a method for determining the fertility of spermatozoa, said method comprising determining the total content of Vimentin variant 3 (Vim3) per spermatozoon and/or the spatial localization of the Vim3 in the spermatozoa, wherein a decreased amount of total content and/or decreased amount of (or even missing) accumulation of Vim3 in the mid piece of the spermatozoa indicates decreased fertility. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.Type: ApplicationFiled: April 6, 2018Publication date: April 9, 2020Applicant: Universität zu KölnInventors: Melanie von Brandenstein, Ali Tok
-
Patent number: 10408834Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: GrantFiled: November 2, 2015Date of Patent: September 10, 2019Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Hildegard Buening, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Pinotossi, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Patent number: 10344053Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.Type: GrantFiled: December 11, 2015Date of Patent: July 9, 2019Assignees: FORSCHUNGSVERBUND BERLIN E.V., UNIVERSITÄT ZU KÖLNInventors: Ronald Kühne, Hans-Günther Schmalz, Matthias Müller, Cedric Reuter, Arne Soicke, Robert Opitz, Matthias Barone, Hartmut Oschkinat